Core Viewpoint - Zhongmu Co., Ltd. has shown a mixed performance in stock price and financial results, with a slight decline in stock price year-to-date but significant growth in revenue and net profit for the first nine months of 2025 [1][2]. Financial Performance - As of September 30, 2025, Zhongmu Co., Ltd. achieved a revenue of 4.442 billion yuan, representing a year-on-year growth of 6.32% [2]. - The net profit attributable to shareholders reached 225 million yuan, marking a substantial increase of 175.49% compared to the previous year [2]. Stock Market Activity - On February 24, Zhongmu Co., Ltd. saw its stock price rise by 2.09%, reaching 7.83 yuan per share, with a trading volume of 63.725 million yuan and a turnover rate of 0.80% [1]. - The company has experienced a year-to-date stock price decline of 0.51%, with a 5-day drop of 1.26%, a 20-day drop of 7.77%, and a 60-day drop of 0.13% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.45% to 36,900, while the average number of tradable shares per person increased by 6.90% to 27,706 shares [2]. - The top ten circulating shareholders include notable entities such as Guotai Junan Zhongzheng Livestock Breeding ETF and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]. Business Overview - Zhongmu Co., Ltd. specializes in animal health products, including vaccines, diagnostic liquids, and veterinary drugs, with its main business revenue composition being: chemical drugs (35.78%), trade (27.87%), feed (19.21%), and biological products (16.10%) [1]. - The company is classified under the agricultural and animal husbandry sector, specifically in animal health [1].

Core Viewpoint - The company, Shanxi Dayu Biological Engineering Co., Ltd., reported a significant increase in revenue for the year 2025, but continued to face net losses, marking the third consecutive year of losses since 2023 [1][2]. Group 1: Financial Performance - The company achieved an operating income of 168 million yuan, representing a year-on-year growth of 36.78% [1]. - The net profit attributable to shareholders was a loss of 28.79 million yuan, which is a 20.23% increase in the loss compared to the previous year [1]. - Total assets are expected to reach 434 million yuan by the end of 2025, reflecting a growth of 10.39% from the beginning of the year [2]. - The equity attributable to shareholders decreased by 9.81% to 265 million yuan, with the net asset per share dropping to 2.39 yuan [2]. - The weighted average return on equity fell to -10.32%, further declining compared to the previous year [2]. Group 2: Business Segments - The revenue growth in 2025 was primarily driven by the newly expanded pig farming business, which contributed 42.19 million yuan to the total revenue [1]. - The pig farming segment's profitability was adversely affected by a significant drop in market prices in the fourth quarter of 2025, leading to increased net losses by 4.84 million yuan compared to the previous year [1]. - Traditional business segments, including feed additives, feed, and veterinary drugs, faced challenges due to industry capacity adjustments and the impact of African swine fever, resulting in a decline in gross profit [1].

Investment Rating - The report maintains an "Outperform" rating for the agriculture, forestry, animal husbandry, and fishery industry [1][4]. Core Views - The report anticipates a reversal in the livestock cycle, particularly benefiting Hong Kong dairy farming stocks [1]. - The monthly recommended stock portfolio includes leading companies in various segments: Yuran Agriculture, Modern Farming, Muyuan Foods, Dekang Agriculture, and Lihua Co., among others [1][3]. - The report highlights the expected upward trend in domestic beef and milk prices, driven by a recovery in the livestock cycle and improved cash flow for leading companies [1][14]. Summary by Sections Livestock Sector - The livestock sector is expected to experience a significant turnaround, with recommendations for Yuran Agriculture and Modern Farming as key beneficiaries [1][14]. - The report notes that domestic beef production capacity is decreasing, which may lead to price increases through 2028 [14]. - The improvement in raw milk prices is anticipated to benefit dairy farming companies, with a projected profit increase for Yuran Agriculture and Modern Farming [17]. Swine Sector - The swine sector is highlighted for its potential recovery, with leading companies like Huazhong, Dekang Agriculture, and Muyuan Foods recommended for investment [1][14]. - The report indicates that the industry is moving towards a more stable price center, supported by a reduction in production capacity and improved cash flow for leading firms [15][20]. Poultry Sector - The poultry sector is expected to see a recovery in demand, with recommendations for Lihua Co. and Shengnong Development [1][18]. - The report notes that the supply of white feather chickens is increasing, but demand is expected to improve, leading to potential price recovery [22][24]. Pet Sector - The pet food market is identified as a growing segment, with a focus on domestic brands like Guibao Pet [1][16]. - The report emphasizes the long-term growth potential of the pet sector, driven by rising consumer sentiment and market expansion [16]. Feed Sector - The feed sector is expected to benefit from deeper industrialization in livestock farming, with leading companies like Haida Group recommended [1][18]. - The report notes that feed prices are at historical lows, providing a strong support level for future price recovery [18].

Core Viewpoint - Limin Co., Ltd. (002734) is experiencing significant growth, with a projected net profit increase of 471.55%-514.57% for 2025 compared to the previous year, indicating strong demand and operational efficiency [1] Group 1: Company Overview - The company offers a diverse range of products including bactericides, insecticides, herbicides, veterinary drugs, soil conditioners, and seed coatings [1] - Limin Co., Ltd. has consistently achieved over 4 billion yuan in annual revenue from 2020 to 2024 [1] Group 2: Financial Projections - The forecast for the annual net profit attributable to shareholders in 2025 is estimated to be between 465 million yuan and 500 million yuan [1] - This represents a substantial growth rate compared to the previous year's performance [1] Group 3: Operational Status - The company reports a strong order backlog and is currently operating at full production and sales capacity [1]

Core Viewpoint - The company, *ST Green Health, is expected to report a negative net profit for the fiscal year 2025, marking the first accounting year after the implementation of financial delisting risk warning on its stock [1][10]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an anticipated net profit being negative [1]. - The company has completed a significant asset restructuring, transferring 100% equity of three subsidiaries to another company, which will affect the financial results [2]. Group 2: Communication with Auditors - The company has communicated with its auditing firm regarding the performance forecast, and there are no significant disagreements as of the announcement date [3]. Group 3: Reasons for Performance Changes - The main reason for the performance change is the separation of the loss-making photovoltaic film business, which will no longer be included in the consolidated financial statements [4]. - Despite the expected loss, the veterinary medicine business has seen revenue growth, primarily from higher-margin products, leading to an overall improvement in gross margin compared to 2024 [4]. Group 4: Risk of Delisting - The company reported a negative net asset value of -24,536,065.37 yuan as of the end of 2024, triggering a delisting risk warning [10][14]. - The net profits attributable to shareholders for 2022, 2023, and 2024 were -121,938,109.79 yuan, -221,817,878.58 yuan, and -444,864,018.29 yuan respectively, indicating a continuous decline [11][14]. - If the company’s financial indicators trigger delisting rules again in 2025, the stock may face termination of listing [24]. Group 5: Audit Progress - The auditing firm, Lixin, has been conducting the 2025 annual audit since November 2025, and there are no major disagreements on significant accounting treatments or key audit matters [25][26]. - The company is actively progressing with the preparation and auditing of the 2025 annual report [25].

Core Viewpoint - *ST Lvkang (002868.SZ) expects a net profit attributable to shareholders of the listed company to be between -140 million and -125 million yuan for 2025, with operating revenue projected to be between 500 million and 515 million yuan [1] Group 1: Financial Performance - The main reason for the company's performance change this year is the expected positive equity attributable to shareholders due to the divestiture of the severely loss-making photovoltaic film business in 2025, which will no longer be included in the consolidated financial statements [1] - The net profit attributable to shareholders is still expected to be a loss primarily due to the losses incurred by the photovoltaic film business before its divestiture, which accounted for over 90% of the losses [1] - The veterinary medicine business has seen revenue growth this year, mainly driven by higher-margin products and an optimized product structure, resulting in an overall improvement in gross margin compared to 2024 [1]

Core Viewpoint - *ST Lvkang (002868.SZ) expects a net profit attributable to shareholders of the listed company to be between -140 million and -125 million yuan for 2025, with operating revenue projected to be between 500 million and 515 million yuan [1] Group 1: Financial Performance - The main reason for the company's performance change this year is the expected positive equity attributable to shareholders due to the divestiture of the loss-making photovoltaic film business in 2025, which will no longer be included in the consolidated financial statements [1] - The net profit attributable to shareholders is still expected to be a loss primarily due to the losses incurred by the photovoltaic film business before the divestiture, which accounted for over 90% of the losses [1] - The veterinary medicine business has seen revenue growth, mainly driven by higher-margin products and an optimized product structure, leading to an overall improvement in gross margin compared to 2024 [1]

Core Viewpoint - The article highlights the dedication and achievements of Du Jihong, a key figure in the veterinary drug quality and animal product safety monitoring in Beijing, emphasizing her role in ensuring food safety and regulatory compliance in the livestock industry [3][4][8]. Group 1: Monitoring and Regulatory Achievements - Du Jihong has been instrumental in leading veterinary drug monitoring efforts, overseeing the inspection of 151 veterinary drug products across 66 enterprises and farms, which has contributed to a high compliance rate in Beijing [4][5]. - Under her leadership, a total of 230 monitoring subjects were tested nearly 4,000 times, successfully identifying illegal additives in veterinary drugs [4][5]. - The establishment of a "1+4+5" tiered monitoring system has allowed for precise management of 18 large-scale breeding enterprises, significantly enhancing the efficiency and accuracy of bacterial resistance monitoring [5][6]. Group 2: Event Support and Emergency Preparedness - During the Beijing 2022 Winter Olympics, Du Jihong led the livestock product safety team, implementing a comprehensive monitoring mechanism that ensured zero errors in product safety during the event [6][7]. - She developed detailed testing plans and sampling protocols, conducting over 20 sampling surveys and completing 386 batches of livestock product tests [6][7]. Group 3: Training and Capacity Building - Du Jihong has organized over 5,000 training sessions for industry professionals, significantly improving the overall monitoring capabilities within the sector [6][7]. - Her efforts in training have led to notable achievements in national skill competitions, showcasing the enhanced skills of participants [6][7]. Group 4: Safety and Risk Management - A strong emphasis on safety has been a hallmark of Du Jihong's work, with the implementation of a three-tier inspection mechanism and the establishment of safety management protocols, resulting in zero accidents at the monitoring center [7][8]. - The proactive approach to safety includes distributing safety manuals and conducting on-site safety checks, contributing to a culture of safety within the veterinary drug industry [7][8].

Group 1 - The core viewpoint of the news is that Limin Co., Ltd. has shown significant financial performance and trading activity, with a notable increase in net profit and a stable financing situation [1][2] Group 2 - On January 15, Limin Co., Ltd. saw a stock price increase of 2.03%, with a trading volume of 493 million yuan. The financing buy-in amount for the day was 99.19 million yuan, while the financing repayment was 43.02 million yuan, resulting in a net financing buy-in of 56.18 million yuan [1] - As of January 15, the total financing and securities balance for Limin Co., Ltd. was 426 million yuan, which accounts for 5.24% of its circulating market value [1] - The company had no shares repaid in the securities lending market on January 15, with 100 shares sold, amounting to 1,710 yuan at the closing price, and a remaining securities lending balance of 900 shares valued at 15,400 yuan [1] Group 3 - As of December 31, the number of shareholders for Limin Co., Ltd. was 56,100, a decrease of 2.03% from the previous period, while the average circulating shares per person increased by 10.12% to 7,747 shares [2] - For the period from January to September 2025, Limin Co., Ltd. achieved an operating income of 3.599 billion yuan, representing a year-on-year growth of 7.62%, and a net profit attributable to shareholders of 390 million yuan, which is a remarkable increase of 661.66% [2] - Since its A-share listing, Limin Co., Ltd. has distributed a total of 918 million yuan in dividends, with 321 million yuan distributed over the past three years [2]

Group 1 - The core viewpoint of the news is that Reap Bio has been recognized as a "Green Factory" for 2025 by the Tianjin Municipal Bureau of Industry and Information Technology, highlighting its leadership in promoting green transformation in the industry [1] - The recognition reflects Reap Bio's strong manufacturing capabilities and its commitment to integrating green and low-carbon development into its core business strategy since its establishment [1] - The evaluation process for the recognition included stringent requirements on energy consumption levels, environmental indicators, and green management systems, prioritizing enterprises with a solid foundation in green low-carbon development [1] Group 2 - In recent years, Reap Bio has aimed to build "smart factories and digital factories," implementing a lean green management system and increasing investments in the integration of intelligence, digitalization, and greening [2] - The company has embedded low-carbon standards throughout the entire process from raw material procurement to production and finished product delivery, utilizing smart production equipment and real-time monitoring systems for energy consumption and emissions [2] - Reap Bio's practices align with the national "14th Five-Year Plan" recommendations to accelerate the high-end, intelligent, and green development of the manufacturing industry, and the company plans to continue its commitment to sustainable development and contribute to high-quality manufacturing and carbon neutrality goals [2]